Subscribe today to receive notice of our latest thought leadership, articles, blogs and updates.
Medicare Insights
Through an integrated medical, pharmacy, claims and legal approach, we deliver insights to help navigate the ever‑changing Medicare Secondary Payer landscape.
Recent blog posts
|
April 20, 2023 · Clinical Team
On April 21, 2023, the ODG Drug Formulary (Appendix A) status will change for several medications within the topical analgesic and nonsteroidal anti-inflammatory (NSAID) classes. Read more... |
|
|
April 06, 2023 · Clinical Team
Our Brand–Generic Pipeline lists new medications approved by the U.S. FDA and first-time generics or brand alternatives that potentially may be prescribed for the treatment of a workers’ compensation or auto injury. The Brand–Generic Pipeline for Q1 2023 is now available -- read it here. Read more... |
|
February 24, 2023 · Medicare Insights Team
On February 17, 2023, CMS announced a delay in the deadline for the final rule on Civil Money Penalties (CMP) from February 18, 2023 to February 18, 2024. Read more... |
|
|
December 15, 2022 · Medicare Insights Team
The Centers for Medicare and Medicaid Services (CMS) held a webinar on December 6, 2022, regarding Section 111 Non-Group Health Plan best practices, compliance tips and common errors. Read more... |
|
|
November 21, 2022 · Medicare Insights Team
On November 14, 2022, The Centers for Medicare and Medicaid Services (CMS) released Version 3.8 of the Workers’ Compensation Medicare Set Aside Arrangement (WCMSA) Reference Guide. Some of the changes/additions in this version pertain to the Re-Review process. Read more... |
|
|
October 31, 2022 · Medicare Insights Team
Optum is closely monitoring the progress and potential impact of a “Final Rule” for Medicare Secondary Payer (MSP) and certain Civil Money Penalties and a “Proposed Rule” regarding MSP and Future Medicals. Both have been under review with the Office of Information and Regulatory Affairs (OIRA) since March 1, 2022. Read more... |
|
|
October 20, 2022 · Clinical Team
When it comes to unused prescription medications, the Drug Enforcement Agency (DEA) encourages everyone to “Keep them safe. Clean them out. Take them back.” They enforce this motto by sponsoring National Prescription Drug Take Back Days. Read more... |
|
|
July 14, 2022 · Clinical Team
Effective June 30, 2022, Zelnorm 6 mg tablet will no longer be produced and marketed in the United States, as announced by its manufacturer, Alfasigma USA, Inc. Read more... |
Page 4 of 7
